Full-Time

Design Assurance Engineer 2

Updated on 7/25/2026

Integer Holdings Corporation

Integer Holdings Corporation

1,001-5,000 employees

Medical device CDMO for cardiac devices

Compensation Overview

$79.2k - $116.2k/yr

+ Incentive

Chaska, MN, USA

In Person

Category
QA & Testing (1)

Get referred to Integer Holdings Corporation

Find people who can refer or advise you

Requirements
  • Earned, as a minimum, a bachelor’s degree in an engineering or related technical field; and have at least three years of relevant experience.
  • Candidates who do not meet the education requirement may be considered with 7+ years of relevant experience.
  • Demonstrate the ability to work independently as well as collaboratively with other associates and cross functional teams.
  • Strong written and oral communication skills, including technical writing.
  • Demonstrated ability to work in a team environment.
  • Solid technical aptitude with the ability to be an effective contributor to a team or produce results of a technical nature as an individual.
  • Functional understanding of the Integer Quality Management Systems and are able to complete required Quality System documentation tasks with little or no direction from others.
  • Demonstrate competency in both written and oral communications.
  • Maintain a calm demeanor that transcends the high energy, constantly changing production environment.
  • Possess a positive, can-do attitude with an underlying belief that failure is not an option.
Responsibilities
  • Adhere to Integer’s Values and all safety, environmental, security and quality requirements including, but not limited to: Quality Management Systems (QMS), Safety, Environmental and Security Management Systems, U.S. Food and Drug Administration (FDA) regulations, company policies and operating procedures, and other regulatory requirements.
  • As a quality Core Team member, actively participates in development project teams. Performs quality/reliability engineering activities to ensure that the design/development procedures, design controls, supplier controls and test requirements are fulfilled.
  • Responsible to generate and execute validation protocols and reports (IEQ,PQ, TMV, SWIQ) for design verification test methods.
  • Support DA lab staff during design verification and design validation protocols execution (test).
  • Collaborates with DA, R&D, and NPI teams to develop, validate, and implement test methods. Leads efforts in fixture design, test method qualification, and creation of clear, accurate work instructions.
  • Drive and support continuous improvement initiatives for legacy test methods.
  • Provides support for root cause analyses, CAPA and Distributed Product Risk Assessment and updates SOPs as required.
  • Initiates, reviews, and approves engineering change requests and documentation.
  • Performs other functions as required.
Integer Holdings Corporation

Integer Holdings Corporation

View

Integer Holdings Corporation is a large medical device contract development and manufacturing organization (CDMO) that supports medical device makers in cardiac rhythm management, neuromodulation, and cardiovascular markets. It provides end-to-end services from design support to manufacturing, delivering components and finished subsystems such as implants, housings, electrodes, and batteries through its Greatbatch Medical, Lake Region Medical, and Electrochem brands. The company differentiates itself by its scale, breadth of capabilities across multiple medical specialties, established brand portfolio, and global manufacturing footprint that enable reliable, integrated supply. Its goal is to improve patients’ lives worldwide by helping customers bring safe and effective medical technologies to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Wilmington, Delaware

Founded

1940

Get referred to Integer Holdings Corporation

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Irenic Capital holds $99M stake as largest disclosed equity holding signaling institutional confidence
  • Underlying business projected to grow 4%-6% organically in 2026 despite new product headwinds
  • Completed $50M share repurchase plus $50M accelerated program under $200M authorization

What critics are saying

  • New Ross plant shutdown July 27-Aug 10, 2026 with unpaid staff causing political backlash
  • Three new products face slower adoption creating 3%-4% 2026 sales headwind and margin compression
  • Class-action fraud lawsuit filed Feb 9, 2026 alleging investor misleading before 32% stock drop

What makes Integer Holdings Corporation unique

  • Integer is a leading global medical device outsource manufacturer with strategic tech investments
  • Specializes in cardiac, vascular, and neurological component manufacturing for interventional cardiology
  • Formerly Greatbatch Inc., renamed in 2016, founded 1970, headquartered in Plano, Texas

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Adoption Assistance

Parental Leave

401(k) Company Match

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Company News

South East Radio
Jul 14th, 2026
New Ross chairman demands meeting with Integer over temporary shut down.

New Ross chairman demands meeting with Integer over temporary shut down. Tuesday, 14 July 2026 09:42 By Aidan Delaney The decision to temporarily close the Integer plant in New Ross over the next few weeks has been described as "mindboggling." The company says an inventory review at the site will necessitate the closure of the plant between July 27th and August 10th. Staff were only informed of this closure last week and will be forced to go without pay for that period. Councillor John Fleming is calling for a meeting between local officials and company bosses to discuss the reasons behind this closure and how it was communicated. He says the sudden nature of this decision is hugely unfair on staff: "You'll have young couples in there trying to start a life, like this will probably affect a mortgage application or their repayments. This is a big kick of them. "I've friends and neighbours working there and they were mindboggled when I spoke to them over the weekend." In a statement to South East Radio News, Integer said it is implementing a temporary operational adjustment at its New Ross facility in response to what it described as a temporary change in customer demand. The company said it is continuing to work closely with customers while maintaining operational readiness, as it expects demand to recover. Integer added that its New Ross facility remains a strategically important operation for the company, and said it has continued to invest in its capacity, capabilities and technology. Councillor Fleming says there was no indication something like this was on the cards and he wants a meeting to hear what's next. "Within the last two years, I was in there and they've expanded and built on around 80,000 square foot and it seemed like everything was booming. "So I just want to go in there and see that this is only a temporary, once off thing and see what is happening so I will be heading in there for clarity." That report was funded by the Local Democracy Reporting Scheme.

Yahoo Finance
Mar 24th, 2026
Integer VP sells $70K in shares as stock drops 28% in a year

Integer Holdings Corporation shares fell 28% following an insider sale disclosure. Tom Thomas, the company's vice president and corporate controller, sold 825 shares of common stock in an open-market transaction on 13 March 2026, according to an SEC Form 4 filing. The transaction was valued at $70,000 at a reported price of $85 per share. The sale represented 15.85% of Thomas's direct holdings at the time. Following the transaction, Thomas holds 4,380 shares worth approximately $364,000. This marks Thomas's third open-market sale since 2018, following previous sales of 884 shares in November and 1,500 shares in April. Integer Holdings manufactures medical devices and components, generating $1.85 billion in trailing twelve-month revenue.

Yahoo Finance
Feb 26th, 2026
Integer Holdings Q4 earnings beat forecasts on strong Cardio & Vascular demand

Integer Holdings, a medical device manufacturer, reported fourth quarter revenue of $472.1 million and adjusted earnings per share of $1.76, both exceeding analyst expectations. The company posted 5% year-on-year revenue growth, driven by strong performance in its Cardio & Vascular segment. CEO Peyman Khales attributed $30 million in operational improvements to higher sales volume, manufacturing efficiencies and expense management. The company guided adjusted earnings per share of $6.54 for 2026, beating analyst estimates by 3.8%. During the earnings call, analysts questioned the narrowing of organic sales guidance, first quarter margin compression and the company's path to above-market growth in 2027. Management emphasised collaborative customer planning and reaffirmed its current strategy despite activist investor involvement.

Intellectia.AI
Feb 23rd, 2026
Irenic Capital takes $99M stake in Integer Holdings as medical device firm posts 8% sales growth

Irenic Capital Management has acquired a $99.11 million stake in Integer Holdings, purchasing 1,263,663 shares in Q4 2026. The position represents 13.7% of Irenic's assets under management, making it the fund's largest disclosed equity holding. Integer Holdings, a medical device company, achieved 8% sales growth in 2025, reaching $1.85 billion in revenue, with adjusted earnings per share rising 21% to $6.40. The company reported fourth-quarter sales of $472 million and net income of $62 million, up 22% year-over-year. Management projects 2026 adjusted earnings per share between $6.29 and $6.78, with plans to achieve organic growth exceeding market rates by 200 basis points in 2027. Benchmark analyst Robert Wasserman upgraded the stock from hold to buy with a $95 price target.

Yahoo Finance
Feb 23rd, 2026
Integer posts 21% adjusted EPS growth but warns of H1 2026 headwinds from slower product adoption

Integer Holdings reported strong 2025 results with sales up 8% and adjusted earnings per share rising 21% to $6.40, alongside margin expansion and $105 million in free cash flow. The company returned capital through a $50 million share repurchase and announced an additional $50 million accelerated share repurchase programme. However, management warned that three newer products representing approximately 6% of 2025 sales are experiencing slower-than-expected adoption, creating a 3%–4% headwind for 2026. The company expects flat-to-slightly-down sales and a 200–250 basis point hit to first-quarter operating margin, with recovery and margin expansion anticipated in the second half. Integer maintained its 2026 midpoint guidance, with year-end net debt expected at $1.17–1.19 billion and net leverage remaining at 3.0 times adjusted EBITDA.